Refractive Surgery
Vision
Therapy: A Progressive Controlled Study on the Effectiveness of Vision Therapy
in Eliminating Asthenopia in a Symptomatic Population
Eligibility Criteria: Patients who are 18 to 35 years of age and have any
of the following symptoms: eye strain, occasional blurred vision when using a
computer or performing other near work, occasional headaches, have words run
together or fall asleep when doing prolonged computer work or near work. If
eligible, participation will involve approximately three visual assessments at
the Cleveland Clinic Division of Ophthalmology at Beachwood and required
equipment for therapy. Compensation of $100 will be allotted for travel
expenses.
Contact: D. Tucker, O.D., at (216) 831-0120 or L. Slaby,
C.O.A., at (330) 963-4843
ACRYSOF Angle-Supported Phakic
Intraocular Lens
Objective: To collect information on the safety and effectiveness
of the artificial lens ACRYSOF for the correction of severe myopia. This study
lens will be implanted behind the cornea in the anterior chamber. The lens is
made of a soft acrylic material that allows the lens to be folded for
implantation and therefore can be inserted through a smaller incision than
other rigid lens designs. Participation in this study will last about 3 years.
Contact: R. Krueger, M.D., at (216) 445-8585 or R. Scott at
(216) 444-0680
Retinal Diseases
A Phase III, Multi-center,
Randomized, Double-masked, Active Treatment -Controlled Study of the Efficacy
and Safety of RHUFAB V2 (Ranibizumab) Compared with Verteporfin (Visudyne)
Photodynamic Therapy in Subjects with Predominantly Classic Subfoveal
Neovascular Age-related Macular Degeneration
Objective: To evaluate the efficacy of intravitreal injections of
ranibizumab administered monthly compared with verteporfin PDT in preventing
vision loss, as measured by the proportion of subjects who lose fewer than 15
letters in visual acuity at 12 months compared with baseline.
Contact: P. Kaiser, M.D., at (216) 444-6702 or L. Holody,
C.O.A., at (216) 445-3762
Protocol B7A-MC-MBDL Reduction
in the Occurrence of Center-Threatening Diabetic Macular Edema
Objective: The primary objective of this study is to test the
hypothesis that oral administration of 32 mg per day of Ruboxistaurin for
approximately 36 months will reduce, relative to placebo, the occurrence of
center-threatening diabetic macular edema as assessed by fundus photography in
patients with non-clinically significant macular edema and nonproliferative
diabetic retinopathy at baseline.
Contact: P. Kaiser, M.D., at (216) 444-6702 or C. Rosal, R.N.,
B.S.N., at (216) 445-1256
A Phase II
Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel
Groups, to Determine the Safety, Efficacy and Pharmacokinetics of Intravitreous
Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in
Patients with Recent Vision Loss Due to Macular Edema Secondary to CRVO
Objective: To determine the effectiveness of pegaptanib sodium in
improving vision in patients with CRVO. Injections or sham will be every 6
weeks with one week post-injection checks throughout the study. The study will
last one year. Patients must have been diagnosed with CRVO within the last 6
months.
Contact: H. Lewis, M.D., at (216) 444-0430 or L. Schaaf, R.N.,
at (216) 445-4086
An Evaluation
of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave
Acetate for Depot Suspension (15 mg or 30 mg) versus Sham Administration
in Patients at Risk for Developing Sight-Threatening Choroidal
Neovascularization Due to Exudative Age‑Related Macular Degeneration
(AMD) AART
Objective: To evaluate the
effectiveness of anecortave acetate in stopping the progression of the “dry” or
early form of AMD to the “wet” or advanced form. Depot administration or sham
(like an injection) will be every six months for four years for a total of nine
visits. Patients must have “wet” AMD in one eye and “dry” AMD in the other.
Vision in the “dry” eye must be equivalent to 20/40 or better.
Contact: P. Kaiser, M.D., at (216) 444-6702 or L. Schaaf, R.N., at (216) 445-4086
The Standard Care versus
Corticosteroid for Retinal Vein Occlusion Study
Objective: To evaluate the effectiveness of triamcinolone
acetonide injections for treatment of macular edema versus standard treatment.
Patients will have 11 to 13 visits over a period of up to three years.
Contact: P. Kaiser, M.D., at (216) 444-6702 or L. Holody,
C.O.A., at (216) 445-3762
A Six-Month
Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month
Open-Label Extension) to Assess the Safety and Efficacy of 700 μg and 350
μg Dexamethasone Posterior Segment Drug Delivery System
Objective: To evaluate the safety and efficacy of the 700 μg DEX PS DDS Applicator System and 350 μg DEX PS DDS Applicator System compared with a Sham
DEX PS DDS Applicator System (needle-less applicator) for six months in
patients with macular edema following branch retinal vein occlusion or central
retinal vein occlusion. The safety of the 700 μg DEX PS DDS Applicator System will be assessed for an
additional 6 months in patients who qualify for treatment in an open-label
safety extension.
Contact: P. Kaiser, M.D., at (216) 444-6702 or L. Schaaf, R.N., at (216) 445-4086
|
